Sweden
· Delayed Price · Currency is SEK ExpreS2ion Biotech Holding AB Company Description
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally.
The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor.
It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical companies.
Further, it sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria; and Evaxion Biotech A/S for development of cytomegalovirus vaccine, as well as partnership agreement with Copenhagen University to develop vaccine for Influenza.
The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
| Country | Sweden |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Bent Frandsen |
Contact Details
Address: ROennowsgatan 8C Helsingborg, 252 25 Sweden | |
| Website | expres2ionbio.com |
Stock Details
| Ticker Symbol | EXPRS2 |
| Exchange | Nasdaq Stockholm |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0008348262 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bent U. Frandsen MSc | Chief Executive Officer |
| Keith Alexander | Chief Financial Officer |
| Dr. Max M. Sogaard | SVice President of Research & Development and Technology and Chief Science Officer |